Robbins R A, Jinkins P A, Bryan T W, Prado S C, Milligan S A
Research Service, Overton Brooks Veterans Administration Medical Center, Shreveport, Louisiana 71101, USA.
Am J Respir Cell Mol Biol. 1998 Jun;18(6):853-9. doi: 10.1165/ajrcmb.18.6.3070.
Nitric oxide (NO) is produced in lung epithelial cells by nitric oxide synthases (NOSs), which can enhance inflammation and edema formation. The inducible NOS (iNOS, type II NOS) has been shown to be increased in lung disorders such as asthma. Therapy for asthma includes antiinflammatory agents such as corticosteroids and antineoplastic agents such as methotrexate (MTX). We hypothesized that NO production by epithelial cells in vitro would be attenuated by MTX, and that this effect would be additive with corticosteroids. In order to test this hypothesis, cells from the murine lung epithelial-cell line LA-4 were cultured to confluence and stimulated to express iNOS and produce NO by cytomix, a combination of human tumor necrosis factor-alpha (TNF-alpha), human interleukin-1beta (IL-1beta) and murine interferon-gamma (IFN-gamma). Nitrite and nitrite + nitrate were measured in the culture supernatant fluids as an index of NO production. MTX caused a dose- and time-dependent inhibition of nitrite and nitrite + nitrate (P < 0.05, all comparisons). Importantly, the inhibition of NO production by MTX (10(-3) M) was additive with dexamethasone (10(-5) to 10(-9) M), but cyclophosphamide, bleomycin, and cytosine-beta-D-arabinofuranoside (Ara-C), other antineoplastic agents, caused no inhibition of NO production. To investigate the mechanism of NO inhibition with MTX, we added tetrahydrobiopterin, which reversed the inhibition. MTX had no effect on the expression of iNOS on Western blotting or iNOS mRNA on Northern blotting. These data show that MTX inhibits NO production by iNOS in murine lung epithelial cells in vitro and that MTX produces added inhibition with corticosteroids, and suggest a potential strategy for reducing NO production in vivo.
一氧化氮(NO)由一氧化氮合酶(NOSs)在肺上皮细胞中产生,这会增强炎症和水肿形成。已表明在诸如哮喘等肺部疾病中,诱导型NOS(iNOS,II型NOS)会增加。哮喘治疗包括抗炎药物如皮质类固醇以及抗肿瘤药物如甲氨蝶呤(MTX)。我们假设MTX会减弱体外培养的上皮细胞产生NO的能力,并且这种作用会与皮质类固醇产生相加效应。为了验证这一假设,将小鼠肺上皮细胞系LA - 4的细胞培养至汇合状态,并通过细胞混合液(一种由人肿瘤坏死因子 - α(TNF - α)、人白细胞介素 - 1β(IL - 1β)和小鼠干扰素 - γ(IFN - γ)组成的混合物)刺激其表达iNOS并产生NO。在培养上清液中测量亚硝酸盐以及亚硝酸盐 + 硝酸盐,以此作为NO产生的指标。MTX导致亚硝酸盐以及亚硝酸盐 + 硝酸盐呈剂量和时间依赖性抑制(所有比较中P < 0.05)。重要的是,MTX(10⁻³ M)对NO产生的抑制作用与地塞米松(10⁻⁵至10⁻⁹ M)具有相加性,但其他抗肿瘤药物环磷酰胺、博来霉素和阿糖胞苷(Ara - C)对NO产生没有抑制作用。为了研究MTX抑制NO产生的机制,我们添加了四氢生物蝶呤,它逆转了这种抑制作用。MTX对蛋白质印迹法检测的iNOS表达或Northern印迹法检测的iNOS mRNA没有影响。这些数据表明,MTX在体外可抑制小鼠肺上皮细胞中iNOS产生NO,并且MTX与皮质类固醇产生相加抑制作用,提示了一种在体内降低NO产生的潜在策略。